Physician profile
Daniel Lawrence Wolfson
NPI 1124230958
$4,148.62
in general payments reported to CMS, 2019-2025
24 companies · $1,259 in 2025
The $1,259 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $321 · 2021: $387 · 2022: $198 · 2023: $1,057 · 2024: $633 · 2025: $1,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,780 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,779.53 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $850.95 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Scientific Affairs, LLC | $521.93 | 2021-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $479.57 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $449.84 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.46 | 2019-2022 | |
| Intra-Sana Laboratories | $250.00 | 2020 | |
| Ardelyx, INC. | $192.54 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $149.52 | 2021-2025 | Eohilia, Entyvio |
| Nuvasive, INC. | $139.42 | 2023 | Xlif |
| Idorsia Pharmaceuticals US INC | $120.85 | 2023 | Quviviq |
| Abbott Laboratories | $96.24 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Braintree Laboratories, INC. | $88.87 | 2020-2025 | Sutab |
| Ipsen Biopharmaceuticals, INC | $78.02 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $68.39 | 2025 | Zenpep |
| Pfizer INC. | $64.91 | 2023-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $58.71 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Allergan, INC. | $56.90 | 2019 | |
| Intercept Pharmaceuticals, INC. | $50.19 | 2023 | Ocaliva |
| Qol Medical, LLC | $41.41 | 2019-2021 | |
| Lilly USA, LLC | $35.73 | 2023-2024 | Omvoh, Mounjaro |
| Exact Sciences Corporation | $29.52 | 2025 | The Cologuard Plus Collection Kit |
| Eisai INC. | $22.77 | 2024 | |
| Merck Sharp & Dohme LLC | $20.97 | 2024 | Dificid |
| Evoke Pharma, INC. | $13.91 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Wolfson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.